- Open Access
Kbus/Idr, a mutant mouse strain with skeletal abnormalities and hypophosphatemia: Identification as an allele of 'Hyp'
© Moriyama et al; licensee BioMed Central Ltd. 2011
- Received: 3 April 2011
- Accepted: 20 August 2011
- Published: 20 August 2011
The endopeptidase encoded by Phex (phosphate-regulating gene with homologies to endopeptidases linked to the X chromosome) is critical for regulation of bone matrix mineralization and phosphate homeostasis. PHEX has been identified from analyses of human X-linked hypophosphatemic rickets and Hyp mutant mouse models. We here demonstrated a newly established dwarfism-like Kbus/Idr mouse line to be a novel Hyp model.
Histopathological and X-ray examination with cross experiments were performed to characterize Kbus/Idr. RT-PCR-based and exon-directed PCR screening performed to identify the presence of genetic alteration. Biochemical assays were also performed to evaluate activity of alkaline phosphatase.
Kbus/Idr, characterized by bone mineralization defects, was found to be inherited in an X chromosome-linked dominant manner. RT-PCR experiments showed that a novel mutation spanning exon 16 and 18 causing hypophosphatemic rickets. Alkaline phosphatase activity, as an osteoblast marker, demonstrated raised levels in the bone marrow of Kbus/Idr independent of the age.
Kbus mice should serve as a useful research tool exploring molecular mechanisms underlying aberrant Phex-associated pathophysiological phenomena.
- Bone defects
- Mouse model
During the maintenance of the KYF/MsIdr strain of mouse, which earlier spontaneously yielded an abnormal behavior-displaying Usher-1D model, BUS/Idr [1, 2], we recognized the occurrence of dwarfism-like short-tailed individuals, which displayed distinct bustling behavior. We have established the mutant as a new strain, Kbus/Idr, through brother-sister mating, and attempted to specify the responsible gene(s), as dealt with in this paper.
Osteogenesis is controlled by osteoblast/osteoclast functional balance in close association with phosphate (Pi) homeostasis regulated by complicated systems operating across the parathyroid gland, intestine, bone and kidney [3, 4]. Parathyroid hormone (PTH), 1,25-vitamin D3 and calcium-sensing receptors constitute the classic pathway of Pi/calcium homeostasis, which is essential for bone differentiation and remodeling. In addition, two important key mediators have been identified through clinical observation and subsequent molecular approaches, fibroblast growth factor-23 (FGF23) and a phosphate-regulating gene product with homology to endopeptidases linked to the X chromosome (PHEX). Gain-of-function mutations of FGF23 lead to autosomal dominant hypophosphatemia/osteomalacia , while its loss-of-function mutations are causative of recessive familial tumoral calcinosis with hyperphosphatemia [6, 7]. FGF23, secreted mainly from osteoblasts/osteocytes [8, 9], is a potent inhibitor of renal Pi reabsorption, leading to phosphate wasting. This phosphaturic hormone binds to renal FGF23 receptor (FGF23r)/Klotho heterodimeric molecules much more tightly than to FGF23r alone, thereby exerting marked inhibitory actions against renal Pi reabsorption [10, 11].
PHEX, another potent mediator of phosphate homeostasis, has been identified from analyses of human X-linked hypophosphatemic rickets (XLH)  and Hyp mutant models [13, 14]. Loss-of-function mutations of PHEX/Phex lead to skeletal abnormalities and hypophosphatemia, and are genetically fully dominant . Aberrant PHEX/Phex expression also results in abnormalities in cartilages [16, 17] and teeth . Phex belongs to the M13-type plasma membrane-integrated metalloendopeptidase family, and is expressed exclusively in cells of the osteoblast/osteocyte lineage [19, 20]. Accumulating evidence indicates that the Phex substrates are protease-resistant acidic serine-aspartate-rich motif peptides (ASARM peptides) generated from small integrin-binding ligand, N-linked glycoproteins (SIBLING proteins) by cathepsin actions [21–29]. Phex interacts with and degrades ASARM peptides of SIBLINGs, such as matrix extracellular phosphoglycoprotein (MEPE), osteopontin and dentin matrix protein 1. Although the SIBLINGs are not highly homologous in structure , their ASARM peptides bind, in a phosphorylation-dependent manner, to matrix Ca × PO4 to inhibit mineralization. Both SIBLINGs and ASARM peptides are increased in Hyp and human XLH and strongly inhibit renal Pi reabsorption [23, 31]. Finally, transgenic mice overexpressing MEPE in bone mimic the Hyp model, displaying growth and mineralization defects with altered bone-renal vascularization .
To date, six Phex mutant models, Hyp (a 3'-deletion of the Phex gene) [13, 14], Gy (partial deletion of both spermine synthase and Phex) [13, 33], Phex(Ska1) (skipping of exon 8) , Hyp-J2 (deletion of exon 15) , Hyp-Duk (deletion of exons 13 and 14) , and Phex(pug) (glycosylation defects due to Phe-to-Ser substitution at a.a. 80 of Phex)  have been reported, while over 260 human disease-associated PHEX mutations have been identified [37–41] http://http:/www.phexdb.mcgill.ca. We have now established a dwarfism-like strain of short-tailed mouse, Kbus/Idr, carrying a novel intragenic deletion of the Phex gene.
Highly inbred Kbus/Idr mice, maintained for over 20 generations were used. Kbus mice were of KYF/MsIdr-origin, and hence KYF mice were used as control animals. All were housed in an air-conditioned room in the Institute for Developmental Research, Aichi Human Service Center, Kasugai, Japan, with a constant temperature (23 ± 1°C) and humidity (55 ± 10%) on a 12:12-hr light-dark cycle with lights on at 7:00 a.m., with free access to standard laboratory diet (CE-2; CLEA Japan Inc.). The animals were handled in accordance with the institute guidelines. Frozen Kbus embryos are now available from RIKEN BioResource Center, Tsukuba, Japan.
Histopathology and X-ray examination
The detailed methods for histopathological examination are described in the legends of Additional file 1, Figure S1 and Additional file 2, Figure S2. To evaluate bone density, age-matched Kbus and KYF mice were subjected to X-ray irradiation at 40 kV and 100 mA for 6 seconds, together with eleven ceramid strips with gradual X-ray transmissivity rates (X-TR), 1 to 11, where X-TR 11 represented the highest TR.
Blood was collected from deeply anesthetized mice, 8 weeks of age, and mixed with an equal volume of 10% trichloroacetic acid and centrifuged at 12,000 × g for 10 min. The supernatants obtained were directly subjected to Pi assay, according to the method of Fiske and SubbaRow . Bone marrow stromal cells (BMSCs) were obtained from the femurs, washed once with phosphate-buffered saline (PBS) and sonicated in 50 mM Tris-1 mM EDTA, pH 6.8, containing 0.1% Triton X-100. Alkaline phosphatase (ALP: osteoblast marker) and tartrate-resistant acid phosphatase (TRAP: osteoclast marker) were assayed at 37°C in 0.1 M glycine-NaOH, pH 10.0, and 0.1 M acetate buffer containing 0.3 M sodium tartrate, pH 4.2, respectively, using 2 mM nitrophenylphosphate (NPP) as the substrate. One unit of enzyme was defined as that releasing 1 μmole of Pi from NPP per min. Protein was measured with a BCA Protein Assay Reagent Kit (Pierce). Serum ALP levels were assessed as described above with x2 diluted serum samples from 14-week-old males. The results were presented as the means ± SEM, and statistically analyzed by Student's t-test, where differences of P < 0.05 were considered significant.
Cross experiments and PCR analysis
The phenotype of all progeny was judged at 8-weeks of age, based on the tail length and dwarfism-like appearance, as well as bustling behavior. The results of Kbus-KYF crosses gave simple segregation patterns in these traits, as shown in the Results section.
For RT-PCR-based screening for mutations of mouse Phex, total RNA fractions were prepared from bony tissues of 3 to 12-day-old mice (Total RNA purification kit; Stratagene). Oligo dT-primed and Phex-specific reverse R6 (Additional file 3, Table S1)-primed first strand cDNAs were prepared using Superscript III (Stratagene), and PCR was carried out with AmpliTaq-Gold (Roche-Applied Biosystems). DNAs were prepared by digestion of homogenized fresh livers with proteinase K in the presence of pancreatic RNase, EDTA and SDS, followed by extraction with phenol. The primer sets used for RT-PCR-based and exon-directed PCR-based screening are shown in Additional file 3, Table S1. The nucleotide sequences of all PCR products were verified with an ABI PRISM 310 genetic analyzer (Applied Biosystems).
Characterization of Kbus/Idr mice
Kbus mice were distinguishable from KYF mice because of a growth defect resulting in a dwarfism-like appearance and short tail (Additional file 1, Figure S1). They exhibited bustling behavior, but swam well, indicating vestibular function to be normal. Kbus mice also exhibited normal startle responses to sounds (popping with hands), indicating that they heard. Since no degenerative features of Corti's organ or spiral ganglion cells were observed in Kbus inner ears (not shown), we concluded that they had no serious inner ear defects. We further noted that the bustling behavior in Kbus was absolutely linked to bone defects in Kbus-KYF crosses, but was almost nullified in F2 progeny of Kbus-C57BL/6 crosses, suggesting the behavioral abnormality to be dependent on the KYF background. Therefore, our primary attention in this study was focused on skeletal abnormalities in Kbus mice.
Identification of Kbus mice linkage to a Hyp allele
Phenotype segregation in cross experiments
F1 progeny of Kbus × KYF
F2 progeny of F1(ab 1 ) × F1(ab)
Backcross of F1(ab) × KYF
F1 progeny of KYF × Kbus
F2 progeny of F1(ab) × F1(n 1 )
Backcross of F1(ab) × Kbus
High alkaline phosphatase activity in isolated Kbus BMSCs
Alkaline phosphatase (AP) and tartrate-resistant acid phosphatase (TRAP) activities in isolated KYF and Kbus BMSCs
KYF (n = 6)
19.7 ± 1.8
61.2 ± 1.8
Kbus (n = 6)
41.7 ± 4.1*
69.4 ± 4.0
KYF (n = 7)
16.9 ± 1.9
58.6 ± 2.2
Kbus (n = 8)
20.6 ± 3.7
52.8 ± 3.4
KYF (n = 8)
8.7 ± 0.7
46.9 ± 2.0
Kbus (n = 8)
18.7 ± 2.9*
43.5 ± 2.3
KYF (n = 6)
7.3 ± 0.3
43.0 ± 3.2
Kbus (n = 6)
14.1 ± 2.7*
45.4 ± 3.6
The present study demonstrated the Kbus strain, here referred to as Hyp(Kbus), to carry a novel genetic alteration of the Phex gene. It was suspected that the distinct bustling behavior and skeletal abnormalities might be controlled by a single gene. Abnormal behavior, such as circling and head tossing and tilting, is a typical sign of inner ear defects in mice [1, 2]; and two Hyp models, Gy and Hyp-Duk [34, 36], have also been reported to display abnormal behavior. However, deafness and endolymphatic hydrops due to the Phex Hyp-Duk mutation exhibit background-dependent variable expression [35, 43]; and in the Gy, alteration of the spermine synthase gene, rather than Phex, is responsible for inner ear defects . We should stress here that the inner ears of Hyp(Kbus) have normal histological features, and their characteristic bustling behavior is relatively slight compared with that of inner ear defect-bearing BUS mice . Furthermore, the behavioral trait was almost nullified in F2 progeny in outcrosses with C57BL/6 mice, suggesting the Hyp(Kbus) behavior to be background-dependent. No clear association between defective PHEX and inner ear defects has been specified in humans, while some XLH patients have hearing impairment .
Hyp models have greatly contributed to our understanding of bone matrix mineralization and maintenance of the Pi balance. Aberration of the Phex-SIBLINGs system leads to remarkable elevation in FGF23 [46–49], and it is now evident that increased levels of FGF23, ASARM and MEPE account for various pathophysiological phenomena described earlier in XLH and Hyp animals. However, the implications and mechanisms of Hyp-induced elevation of FGF23 have remained unclear, because the main sites of FGF23 production are osteoblasts/osteocytes [8, 9], and because Phex deficiency should result in diminished osteogenesis. Equally unclear have been the source and implications of increased serum ALP activity in Phex deficiency. In general, serum ALP activity and the number of ALP-positive osteoprogenitor cells in BMSC culture correlate with bone-forming ability and bone density . In Hyp models, however, this is not the case, because cultured Hyp BMSCs exhibit reduced osteoblastogenesis and skeletogenesis [24–26]. Based on the present finding that isolated Hyp(Kbus) BMSCs exhibit significantly elevated ALP activity, we suggest that ALP-containing osteoblast-like cells in the bone marrow are the source of ALP increase in serum, further indicating that most of these ALP-positive BMSCs could be non-adherent or unable to survive in culture. It is necessary to specify the role and the fate of ALP-positive cells abundant in Hyp(Kbus) bone marrow.
Hyp models have another important contribution as research tools for therapeutic approaches. It appears that rescue of the Hyp phenotype can be accomplished by expression of the PHEX transgene over a long period of time under control of a bone-specific promoter , although in some reports there was only partial rescue by the transgene of Hyp abnormalities [52–54]. Recently, it has been noted that Hyp/klotho-/- knockout mice lack the hypophosphatemia and mineralization defects of Hyp, but with a shortened life span [55, 56]. Hyp models can be expected to play a part in providing further clues to therapeutic manipulation of Pi balance-associated disorders.
Histopathological and molecular genetic analyses here demonstrated a newly established dwarfism-like Kbus/Idr mouse line to be a novel Hyp model. The mutant could be important as a tool in further dissection and understanding of regulatory mechanisms of bone mineralization and Pi homeostasis, and in assessment of therapeutic aspects of human bone/Pi-associated disorders.
- Moriyama K, Hashimoto R, Hanai A, Yoshizaki N, Yonezawa S, Otani H: Degenerative hairlets on the vestibular sensory cells in mutant bustling (BUS/Idr) mice. Acta Otolaryn. 1997, 117: 20-24. 10.3109/00016489709117985.View ArticleGoogle Scholar
- Yonezawa S, Yoshizaki N, Kageyama T, Takahashi T, Sano M, Tokita Y, Masaki S, Inaguma Y, Hanai A, Sakurai N, Yoshiki A, Kusakabe M, Moriyama A, Nakayama A: Fates of Cdh23/CDH23 with mutations affecting the cytoplasmic region. Hum Mutat. 2006, 27: 88-97. 10.1002/humu.20266.View ArticlePubMedGoogle Scholar
- Kiela PR, Ghishan FK: Recent advances in the renal-skeletal-gut axis that controls phosphate homeostasis. Lab Invest. 2009, 89: 7-14. 10.1038/labinvest.2008.114.PubMed CentralView ArticlePubMedGoogle Scholar
- Bergwitz C, Jüppner H: Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Ann Rev Med. 2010, 61: 91-104. 10.1146/annurev.med.051308.111339.View ArticlePubMedGoogle Scholar
- ADHR Consortium: Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF-23. Nat Genet. 2000, 26: 345-348. 10.1038/81664.View ArticleGoogle Scholar
- Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE: A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab. 2005, 90: 2424-2427. 10.1210/jc.2004-2238.View ArticlePubMedGoogle Scholar
- Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, White KE: Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology. 2005, 146: 3883-3891. 10.1210/en.2005-0431.View ArticlePubMedGoogle Scholar
- Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne K, Aubin JE, Maeda N: Mineralized tissue cells are a principal source of FGF23. Bone. 2007, 40: 1565-1573. 10.1016/j.bone.2007.01.017.View ArticlePubMedGoogle Scholar
- Ubaidus S, Li M, Sultana S, de Freitas PH, Oda K, Maeda T, Takagi R, Amizuka N: FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J Electron Microsc (Tokyo). 2009, 56: 381-392.View ArticleGoogle Scholar
- Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF-23. Nature. 2006, 444: 770-774. 10.1038/nature05315.View ArticlePubMedGoogle Scholar
- Razzaque MS, Lanske B: The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol. 2007, 194: 1-10. 10.1677/JOE-07-0095.PubMed CentralView ArticlePubMedGoogle Scholar
- The HYP Consortium: A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet. 1995, 11: 130-136. 10.1038/ng1095-130.View ArticleGoogle Scholar
- Strom TM, Francis F, Lorenz B, Böddrich A, Econs MJ, Lehrach H, Meitinger T: Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet. 1997, 6: 165-171. 10.1093/hmg/6.2.165.View ArticlePubMedGoogle Scholar
- Beck L, Soumounou Y, Martel J, Krishnamurthy G, Gauthier C, Goodyer CG, Tenenhouse HS: Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest. 1997, 99: 1200-1209. 10.1172/JCI119276.PubMed CentralView ArticlePubMedGoogle Scholar
- Qiu ZQ, Travers R, Rauch F, Glorieux FH, Scriver CR, Tenenhouse HS: Effect of gene dose and parental origin on bone histomorphometry in X-linked Hyp mice. Bone. 2004, 34: 134-139. 10.1016/j.bone.2003.09.004.View ArticlePubMedGoogle Scholar
- Miao D, Bai X, Panda DK, Karaplis AC, Goltzman D, McKee MD: Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice. Bone. 2004, 34: 638-647. 10.1016/j.bone.2003.12.015.View ArticlePubMedGoogle Scholar
- Liang G, Katz LD, Insogna KL, Carpenter TO, Macica CM: Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice. Calcif Tissue Int. 2009, 85: 235-246. 10.1007/s00223-009-9270-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Fong H, Chu EY, Tompkins KA, Foster BL, Sitara D, Lanske B, Somerman MJ: Aberrant cementum phenotype associated with the hypophosphatemic hyp mouse. J Periodontol. 2009, 80: 1348-1354. 10.1902/jop.2009.090129.PubMed CentralView ArticlePubMedGoogle Scholar
- Sabbagh Y, Tenenhouse HS, Roche PC, Drezner MK, Salisbury JL, Grande JP, Poeschla EM, Kumar R: Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts. J Bone Miner Res. 2002, 17: 311-320. 10.1359/jbmr.2002.17.2.311.View ArticlePubMedGoogle Scholar
- Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK: Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest. 2008, 118: 722-734.PubMed CentralPubMedGoogle Scholar
- Guo R, Rowe PS, Liu S, Simpson LG, Xiao ZS, Quarles LD: Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun. 2002, 297: 38-45. 10.1016/S0006-291X(02)02125-3.View ArticlePubMedGoogle Scholar
- Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR: MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004, 34: 303-319. 10.1016/j.bone.2003.10.005.PubMed CentralView ArticlePubMedGoogle Scholar
- Bresler D, Bruder J, Mohnike K, Fraser WD, Rowe PS: Serum EMPE-ASARM-peptides are elevated in X-linked rickets (HYP):Implications for phosphaturia and rickets. J Endocrinol. 2004, 183: R1-R9. 10.1677/joe.1.05989.PubMed CentralView ArticlePubMedGoogle Scholar
- Rowe PS, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, Gutierrez GE: Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif:a model for impaired mineralization in X-linked rickets (HYP). Bone. 2005, 36: 33-46. 10.1016/j.bone.2004.09.015.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu S, Rowe PSN, Vierthaler L, Zhou J, Quarles LD: Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol. 2007, 192: 261-267. 10.1677/joe.1.07059.PubMed CentralView ArticlePubMedGoogle Scholar
- Addison WN, Nakano Y, Loisel T, Crine P, McKee MD: MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res. 2008, 23: 1638-1649. 10.1359/jbmr.080601.View ArticlePubMedGoogle Scholar
- Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS: Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology. 2008, 149: 1757-1772. 10.1210/en.2007-1205.PubMed CentralView ArticlePubMedGoogle Scholar
- Addison WN, Masica DL, Gray JJ, McKee MD: Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res. 2010, 25: 695-705.View ArticlePubMedGoogle Scholar
- Boukpessi T, Gaucher C, Léger T, Salmon B, Le Faouder J, Willig C, Rowe PS, Garabédian M, Meilhac O, Chaussain C: Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin. Am J Pathol. 2010, 177: 803-812. 10.2353/ajpath.2010.091231.PubMed CentralView ArticlePubMedGoogle Scholar
- Fisher LW, Fedarko NS: Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res. 2003, 44 (Suppl1): 33-40.View ArticlePubMedGoogle Scholar
- Dobbie H, Unwin RJ, Faria NJ, Shirley DG: Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant. 2007, 23: 730-733. 10.1093/ndt/gfm535.View ArticlePubMedGoogle Scholar
- David V, Martin A, Hedge A-N, Rowe PSN: Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology. 2009, 150: 4012-4023. 10.1210/en.2009-0216.PubMed CentralView ArticlePubMedGoogle Scholar
- Meyer RA, Henley CM, Meyer MH, Morgan PL, Mc-Donald AG, Mills C, Price DK: Partial deletion of both the spermine synthase gene and the Pex gene in the X-linkedhypophosphatemic, gyro (Gy) mouse. Genomics. 1998, 48: 289-295. 10.1006/geno.1997.5169.View ArticlePubMedGoogle Scholar
- Carpinelli MR, Wicks IP, Sims NA, O'Donnell K, Hanzinikolas K, Burt R, Foote SJ, Bahlo M, Alexander WS, Hilton DJ: An ethyl-nitrosourea-induced point mutation in phex causes exon skipping, x-linked hypophosphatemia, and rickets. Am J Pathol. 2002, 161: 1925-1933. 10.1016/S0002-9440(10)64468-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Lorenz-Depiereux B, Guido VE, Johnson KR, Zheng QY, Gagnon LH, Bauschatz JD, Davisson MT, Washburn LL, Donahue LR, Strom TM, Eicher EM: New intragenic deletions in the Phex gene clarify X-linked hypophosphatemia-related abnormalities in mice. Mamm Genome. 2004, 15: 151-161. 10.1007/s00335-003-2310-z.PubMed CentralView ArticlePubMedGoogle Scholar
- Xiong X, Qi X, Ge X, Gu P, Zhao J, Zhao Q, Gao X: A novel Phex mutation with defective glycosylation causes hypophosphatemia and rickets in mice. J Biomed Sci. 2008, 15: 47-59.View ArticlePubMedGoogle Scholar
- Holm IA, Nelson AE, Robinson BG, Mason RS, Marsh DJ, Cowell CT, Carpenter TO: Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2001, 86: 3889-3899. 10.1210/jc.86.8.3889.View ArticlePubMedGoogle Scholar
- Ichikawa S, Traxler EA, Estwick SA, Curry LR, Johnson ML, Sorenson AH, Imel EA, Econs MJ: Mutational survey of the PHEX gene in patients with X-linked hypophosphatemic rickets. Bone. 2008, 43: 663-666. 10.1016/j.bone.2008.06.002.PubMed CentralView ArticlePubMedGoogle Scholar
- Makras P, Hamdy NA, Kant SG, Papapoulos SE: Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene. J Clin Endocrinol Metab. 2008, 93: 1386-1389. 10.1210/jc.2007-1296.View ArticlePubMedGoogle Scholar
- Gaucher C, Walrant-Debray O, Nguyen T-M, Esterle L, Garabédian M, Jehan F: PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. Hum Genet. 2009, 125: 401-411. 10.1007/s00439-009-0631-z.View ArticlePubMedGoogle Scholar
- Ruppe MD, Brosnan PG, Au KS, Tran PX, Dominguez BW, Northrup H: Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets. Clin Endocrinol (Oxf). 2011, 74: 312-318. 10.1111/j.1365-2265.2010.03919.x.View ArticleGoogle Scholar
- Fiske CH, SubbaRow Y: The colorimetric determination of phosphorus. J Biol Chem. 1925, 66: 375-400.Google Scholar
- Megerian CA, Semaan MT, Aftab S, Kisley LB, Zheng QY, Pawlowski KS, Wright CG, Alagramam KN: A mouse model with postnatal endolymphatic hydrops and hearing loss. Hear Res. 2008, 237: 90-105. 10.1016/j.heares.2008.01.002.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang X, Levic S, Gratton MA, Doyle KJ, Yamoah EN, Pegg AE: Spermine synthase deficiency leads to deafness and a profound sensitivity to alpha-difluoromethylornithine. J Biol Chem. 2009, 284: 930-937.PubMed CentralView ArticlePubMedGoogle Scholar
- Fishman G, Miller-Hansen D, Jacobsen C, Singhal VK, Alon US: Hearing impairment in familial X-linked hypophosphatemic rickets. Eur J Pediatr. 2004, 163: 622-623.PubMedGoogle Scholar
- Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S: Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002, 87: 4957-4960. 10.1210/jc.2002-021105.View ArticlePubMedGoogle Scholar
- Weber TJ, Liu S, Indridason OS, Quarles LD: Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003, 18: 1227-1234. 10.1359/jbmr.2003.18.7.1227.View ArticlePubMedGoogle Scholar
- Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003, 348: 1656-1663. 10.1056/NEJMoa020881.View ArticlePubMedGoogle Scholar
- Onishi T, Umemura S, Shintani S, Ooshima T: Phex mutation causes overexpression of FGF23 in teeth. Arch Oral Biol. 2008, 53: 99-104. 10.1016/j.archoralbio.2007.08.009.View ArticlePubMedGoogle Scholar
- Dimai HP, Linkhart TA, Linkhart SG, Donahue LR, Beamer WG, Rosen CJ, Farley JR, Baylink DJ: Alkaline phosphatase levels and osteoprogenitor cell numbers suggest bone formation may contribute to peak bone density differences between two inbred strains of mice. Bone. 1998, 22: 211-216. 10.1016/S8756-3282(97)00268-8.View ArticlePubMedGoogle Scholar
- Boskey A, Frank A, Fujimoto Y, Spevak L, Verdelis K, Ellis B, Troiano N, Philbrick W, Carpenter T: The PHEX transgene corrects mineralization defects in 9-month-old hypophosphatemic mice. Calcif Tissue Int. 2009, 84: 126-137. 10.1007/s00223-008-9201-y.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu S, Guo R, Tu Q, Quarles LD: Overexpression of Phex in osteoblasts fails to rescure the Hyp mouse phenotype. J Biol Chem. 2002, 277: 3686-3697. 10.1074/jbc.M107707200.View ArticlePubMedGoogle Scholar
- Bai X, Miao D, Panda D, Grady S, McKee MD, Goltzman D, Karaplis AC: Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases onn the X chromosome) expression. Mol Endocrinol. 2002, 16: 2913-2925. 10.1210/me.2002-0113.View ArticlePubMedGoogle Scholar
- Erben GR, Mayer D, Weber K, Jonsson K, Juppner H, Lanske B: Overexpression of human PHEX under the human beta-actin promotor does not fully rescue the Hyp mouse phenotype. J Bone Miner Res. 2005, 20: ; 1149-1160.View ArticlePubMedGoogle Scholar
- Nakatani T, Ohnishi M, Razzaque S: Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J. 2009, 23: 3702-3711. 10.1096/fj.08-123992.PubMed CentralView ArticlePubMedGoogle Scholar
- Brownstein CA, Zhang J, Stillman A, Ellis B, Troiano N, Adams DJ, Gundberg CM, Lifton RP, Carpenter TO: Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse. Endocrinology. 2010, 151: 492-501. 10.1210/en.2009-0564.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.